SCHEMBL2767151

SCHEMBL2767151

O=C(Cc1ccc(Cl)cc1)N1CCN(c2ccc(O)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 5/20 1.00
ME1 P48163 5/20 1.00
ME3 Q16798 5/20 1.00
KMT2A Q03164 3/20 0.78
MEN1 O00255 2/20 0.78
GFER P55789 2/20 0.77
ATM Q13315 1/20 0.77
POLB P06746 1/20 0.65
MAPT P10636 4/20 0.63
NPC1 O15118 1/20 0.63
GAA P10253 1/20 0.63
MAPK1 P28482 1/20 0.63
RAB9A P51151 1/20 0.63
AKR1C3 P42330 1/20 0.59
CA12 O43570 1/20 0.59
CA2 P00918 1/20 0.59
CA9 Q16790 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
GRM5 P41594 1/20 0.57
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23244396 0.93 ME2 (0.86) ME2ME1ME3KMT2AMEN1
SCHEMBL11076871 0.87 GFER (0.89) ME2ME1ME3KMT2AMEN1
SCHEMBL10902216 0.86 GFER (0.78) ME2ME1ME3KMT2AMEN1
SCHEMBL23244223 0.85 ME3 (1.00) ME2ME1ME3KMT2AMEN1
SCHEMBL23244286 0.82 ME2 (1.00) ME2ME1ME3KMT2AMEN1
SCHEMBL29666895 0.82 ME2 (0.69) ME2ME1ME3KMT2AMEN1
SCHEMBL9568359 0.81 ME2 (0.67) ME2ME1ME3KMT2AMEN1
SCHEMBL5539457 0.79 ME2 (0.63) ME2ME1ME3KMT2AMEN1
SCHEMBL23244264 0.79 ME2 (0.78) ME2ME1ME3KMT2AMEN1
SCHEMBL10981623 0.79 ME2 (0.64) ME2ME1ME3KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
CN-100467449-C Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2009-03-11 CN disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
CN-1823039-A Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2006-08-23 CN disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA ME2 976/4885ME1 746/4885ME3 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.